HLB Therapeutics

At a glance

HLB Therapeutics filed 60 disclosures in the last 12 months, including 10 5% holder, 8 insider, 3 issuance and 1 contract. The most recent key filing was on Oct 21: A major holder's stake rose from 20.05% to 20.14% (open-market buy).

Revenue for 2025 was ₩69.6B, up 26.6% on 2024. It made an operating loss of ₩3.5B. Debt was 32% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩25.6B and operating loss of ₩8B.

The 2025 annual report lists 50 employees with an average tenure of 2.7 years and average pay of ₩48.6M, #1510 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩49.6M each on average. It paid no cash dividend for 2025. 에이치엘비(주) and related parties held 12.70% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 20.14% on Oct 21.

From the 2025 annual report

Staff: 50 (36 men, 14 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩2.4B. Directors and auditors: 6, paid ₩297.4M in total.

No cash dividend was paid for 2025.

Largest shareholder

에이치엘비(주) holds 7.94%; with 9 related parties the group holds 12.70% of common shares at year end (from 12.73% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports